Artivion’s (AORT) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Artivion (NYSE:AORT) in a report released on Wednesday,Weiss Ratings reports.

Several other research firms have also recently commented on AORT. Wall Street Zen upgraded Artivion from a “hold” rating to a “buy” rating in a research report on Monday, August 25th. Stifel Nicolaus boosted their price objective on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. JMP Securities boosted their price target on shares of Artivion from $33.00 to $42.00 and gave the stock a “market outperform” rating in a research note on Friday, August 8th. LADENBURG THALM/SH SH cut shares of Artivion from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Finally, Canaccord Genuity Group upped their price objective on Artivion from $41.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.97.

Artivion Price Performance

Shares of NYSE:AORT opened at $40.21 on Wednesday. The company has a 50 day moving average of $41.29 and a 200 day moving average of $32.51. The stock has a market cap of $1.90 billion, a P/E ratio of -95.74 and a beta of 1.67. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. Artivion has a 12 month low of $21.97 and a 12 month high of $45.07.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. The firm had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion’s revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling

In other Artivion news, insider John E. Davis sold 10,802 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the sale, the insider owned 208,778 shares of the company’s stock, valued at $9,117,335.26. This represents a 4.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total transaction of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares of the company’s stock, valued at $2,826,084. The trade was a 22.09% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 74,858 shares of company stock worth $3,250,129. 7.60% of the stock is owned by company insiders.

Institutional Trading of Artivion

A number of institutional investors have recently modified their holdings of AORT. Legacy Advisors LLC purchased a new stake in Artivion in the 1st quarter worth approximately $28,000. MCF Advisors LLC lifted its stake in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after acquiring an additional 614 shares during the period. Smartleaf Asset Management LLC lifted its stake in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the period. Tower Research Capital LLC TRC lifted its stake in Artivion by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after acquiring an additional 4,422 shares during the period. Finally, James Investment Research Inc. purchased a new stake in Artivion in the second quarter worth $210,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.